drugset / Trial / NCT04158102
Evaluate the Pharmacokinetics and Safety of EXPAREL® Following Subcutaneous Administration in Healthy Chinese Subjects
NaSingle-groupOpen-labelOther
Summary
This is a single-center, open-label, single-dose study to evaluate the safety, pharmacokinetics in healthy subjects
Timeline
- Start
- 2019-11-07
- Primary completion
- 2019-12-17
- Completion
- 2019-12-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupivacaine | Other / unclassified | 266 mg | Subcutaneous |
Indications
No indication recorded.